Compare

UL Solutions Inc. vs 20/20 Biolabs, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	UL Solutions Inc. ULS	20/20 Biolabs, Inc. AIDX
Year ended	2025-12-31	2025-12-31
Revenue	$3.05B	$2.05M
Revenue growth (YoY)	+6.4%	+16.7%
Gross margin	49.5% (computed)	29.6%
Operating margin	17.1%	-162.9%
Net margin	10.6%	-182.8%
Net income	$325.00M	-$3.74M
EPS (Diluted)	$1.60	-$0.76
Operating cash flow	$600.00M	-$1.92M
Free cash flow	$403.00M	n/a
Cash & equivalents	$295.00M	$1.03M
Total assets	$2.92B	$4.14M
Total liabilities	$1.63B	$4.16M
Shareholders' equity	$1.29B	-$19.2K
Return on year-end equity	25.1%	n/a
Shares outstanding	201.03M	5.44M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	UL Solutions Inc.	20/20 Biolabs, Inc.
Latest	$3.05B Ended 2025-12-31	$2.05M Ended 2025-12-31
1 year earlier	$2.87B Ended 2024-12-31	$1.75M Ended 2024-12-31
2 years earlier	$2.68B Ended 2023-12-31	n/a
3 years earlier	$2.52B Ended 2022-12-31	n/a
4 years earlier	n/a	n/a